Phantom limb pain and central post-stroke pain
Neuropathic pain · C8 · Reviewed by a board-certified pain physician on November 2, 2026
Bottom line
Central post-stroke pain is burning or aching pain in the stroke-affected territory, often after thalamic or brainstem lesions, treated like other neuropathic pain; phantom limb pain is common after amputation, and mirror therapy is the most studied nondrug option.
Key points
- Central post-stroke pain appears after a latency. It is neuropathic pain in part of the body affected by hemorrhagic or ischemic stroke, usually developing within a few months 1.
- Lesion site matters. Thalamic and brainstem lesions are more likely to cause central neuropathic pain than lesions elsewhere 1.
- The sensory picture is mixed. Burning, aching or stabbing pain combines hypo- and hypersensitivity; over 90% have thermal, especially cold, sensory abnormalities, while touch and vibration deficits are less common 1.
- Treat as central neuropathic pain. Amitriptyline is widely supported as first-line for post-stroke pain, with gabapentinoids, duloxetine and lamotrigine as options; NeuPSIG 2025 lists gabapentinoids, SNRIs and TCAs as first-line for neuropathic pain generally 12.
- Phantom limb pain is very common. About 80% of amputees report it in the first year and up to 87% at some point 3.
- Mirror therapy is the leading nondrug option. Reflected movement of the intact limb gives the illusion that the missing limb moves; in 32 studies, 21 reported clinically significant reduction, but protocols vary widely. Phantom pain is linked to peripheral and central changes, including cortical reorganization 3.
Watch for
Not all pain after stroke is central: shoulder pain and other post-stroke pains must be distinguished, and the lack of clear diagnostic criteria makes prevalence estimates uncertain 1.
High-yield for the exam
- Central post-stroke pain affects about 1–12% of stroke patients, reportedly up to 55% 1.
- Intermittent dysesthesia occurs in up to 85% of central post-stroke pain patients 1.
- Amitriptyline is typically given at about 75 mg/day for central post-stroke pain 1.
- In a mixed neuropathic cohort including central post-stroke pain, oral opioids lowered pain by about 23% on average 1.
- Refractory central post-stroke pain may be considered for deep brain or motor cortex stimulation 1.
- Mirror therapy versus covered-mirror sham showed no significant difference, suggesting phantom motor execution may be the active component 3.
- Virtual mirror therapy delivers visual feedback digitally and can track adherence in home programs 3.
- No unanimous consensus exists on mirror therapy setting, technique, session frequency or duration 3.
Numbers to know
| Item | Value |
|---|---|
| CPSP prevalence after stroke | 1–12% (up to 55%) 1 |
| CPSP with thermal abnormality | >90% 1 |
| Amitriptyline usual dose | ~75 mg/day 1 |
| Lamotrigine dose studied in CPSP | 200 mg/day 1 |
| Phantom pain in first year | ~80% 3 |
| Lifetime phantom pain | up to 87% 3 |
| Mirror studies with clinically significant benefit | 21 of 32 3 |
Common traps
Practise this topic
7 more questions on this topic in the full question bank, with explanations and sources.
Sources
- Asadauskas A, et al. Advancements in modern treatment approaches for central post-stroke pain: a narrative review. J Clin Med, 2024. pmc.ncbi.nlm.nih.gov/articles/PMC11432561/
- Soliman N, et al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol, 2025. pubmed.ncbi.nlm.nih.gov/40252663/
- Limakatso K, et al. Evaluating mirror therapy protocols in phantom limb pain clinical trials: a scoping review. J Pain Res, 2025. pmc.ncbi.nlm.nih.gov/articles/PMC11812563/
Related topics
Independent study material for the ABA Pain Medicine exam, written and reviewed by a board-certified pain physician. Not medical advice; not affiliated with the American Board of Anesthesiology.